203 related articles for article (PubMed ID: 36112789)
1. Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis.
Vaishnavi A; Juan J; Jacob M; Stehn C; Gardner EE; Scherzer MT; Schuman S; Van Veen JE; Murphy B; Hackett CS; Dupuy AJ; Chmura SA; van der Weyden L; Newberg JY; Liu A; Mann K; Rust AG; Weiss WA; Kinsey CG; Adams DJ; Grossmann A; Mann MB; McMahon M
Cancer Res; 2022 Nov; 82(22):4261-4273. PubMed ID: 36112789
[TBL] [Abstract][Full Text] [Related]
2. Diminished WNT -> β-catenin -> c-MYC signaling is a barrier for malignant progression of BRAFV600E-induced lung tumors.
Juan J; Muraguchi T; Iezza G; Sears RC; McMahon M
Genes Dev; 2014 Mar; 28(6):561-75. PubMed ID: 24589553
[TBL] [Abstract][Full Text] [Related]
3. MEK1/2 inhibition elicits regression of autochthonous lung tumors induced by KRASG12D or BRAFV600E.
Trejo CL; Juan J; Vicent S; Sweet-Cordero A; McMahon M
Cancer Res; 2012 Jun; 72(12):3048-59. PubMed ID: 22511580
[TBL] [Abstract][Full Text] [Related]
4. RBMS3 is a tumor suppressor gene that acts as a favorable prognostic marker in lung squamous cell carcinoma.
Liang YN; Liu Y; Meng Q; Li X; Wang F; Yao G; Wang L; Fu S; Tong D
Med Oncol; 2015 Feb; 32(2):459. PubMed ID: 25588924
[TBL] [Abstract][Full Text] [Related]
5. Autophagy promotes BrafV600E-driven lung tumorigenesis by preserving mitochondrial metabolism.
Strohecker AM; White E
Autophagy; 2014 Feb; 10(2):384-5. PubMed ID: 24362353
[TBL] [Abstract][Full Text] [Related]
6. RBMS3 at 3p24 inhibits nasopharyngeal carcinoma development via inhibiting cell proliferation, angiogenesis, and inducing apoptosis.
Chen J; Kwong DL; Zhu CL; Chen LL; Dong SS; Zhang LY; Tian J; Qi CB; Cao TT; Wong AM; Kong KL; Li Y; Liu M; Fu L; Guan XY
PLoS One; 2012; 7(9):e44636. PubMed ID: 22957092
[TBL] [Abstract][Full Text] [Related]
7. RBMS3 Inhibits the Proliferation and Metastasis of Breast Cancer Cells.
Yang Y; Quan L; Ling Y
Oncol Res; 2018 Jan; 26(1):9-15. PubMed ID: 28409548
[TBL] [Abstract][Full Text] [Related]
8. Mutationally activated PIK3CA(H1047R) cooperates with BRAF(V600E) to promote lung cancer progression.
Trejo CL; Green S; Marsh V; Collisson EA; Iezza G; Phillips WA; McMahon M
Cancer Res; 2013 Nov; 73(21):6448-61. PubMed ID: 24019382
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of RBMS3 is associated with poor prognosis in esophageal squamous cell carcinoma.
Li Y; Chen L; Nie CJ; Zeng TT; Liu H; Mao X; Qin Y; Zhu YH; Fu L; Guan XY
Cancer Res; 2011 Oct; 71(19):6106-15. PubMed ID: 21844183
[TBL] [Abstract][Full Text] [Related]
10. TP53 Silencing Bypasses Growth Arrest of BRAFV600E-Induced Lung Tumor Cells in a Two-Switch Model of Lung Tumorigenesis.
Shai A; Dankort D; Juan J; Green S; McMahon M
Cancer Res; 2015 Aug; 75(15):3167-80. PubMed ID: 26001956
[TBL] [Abstract][Full Text] [Related]
11. Adverse Event Management in Patients with
Chalmers A; Cannon L; Akerley W
Oncologist; 2019 Jul; 24(7):963-972. PubMed ID: 30598499
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of MUC1-C Suppresses MYC Expression and Attenuates Malignant Growth in KRAS Mutant Lung Adenocarcinomas.
Bouillez A; Rajabi H; Pitroda S; Jin C; Alam M; Kharbanda A; Tagde A; Wong KK; Kufe D
Cancer Res; 2016 Mar; 76(6):1538-48. PubMed ID: 26833129
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Dabrafenib and Trametinib in a Patient with Squamous-Cell Carcinoma, with Mutation p.D594G in
Grenda A; Krawczyk P; Targowska-Duda KM; Kieszko R; Paśnik I; Milanowski J
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674722
[TBL] [Abstract][Full Text] [Related]
14. Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma.
Marsh Durban V; Deuker MM; Bosenberg MW; Phillips W; McMahon M
J Clin Invest; 2013 Dec; 123(12):5104-18. PubMed ID: 24200692
[TBL] [Abstract][Full Text] [Related]
15. DDX5 promotes proliferation and tumorigenesis of non-small-cell lung cancer cells by activating β-catenin signaling pathway.
Wang Z; Luo Z; Zhou L; Li X; Jiang T; Fu E
Cancer Sci; 2015 Oct; 106(10):1303-12. PubMed ID: 26212035
[TBL] [Abstract][Full Text] [Related]
16. Down regulation of RNA binding motif, single-stranded interacting protein 3, along with up regulation of nuclear HIF1A correlates with poor prognosis in patients with gastric cancer.
Wu Y; Yun D; Zhao Y; Wang Y; Sun R; Yan Q; Zhang S; Lu M; Zhang Z; Lu D; Li Y
Oncotarget; 2017 Jan; 8(1):1262-1277. PubMed ID: 27902480
[TBL] [Abstract][Full Text] [Related]
17. MYC synergizes with activated BRAFV600E in mouse lung tumor development by suppressing senescence.
Tabor V; Bocci M; Alikhani N; Kuiper R; Larsson LG
Cancer Res; 2014 Aug; 74(16):4222-9. PubMed ID: 24934810
[TBL] [Abstract][Full Text] [Related]
18. A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors.
Dankort D; Filenova E; Collado M; Serrano M; Jones K; McMahon M
Genes Dev; 2007 Feb; 21(4):379-84. PubMed ID: 17299132
[TBL] [Abstract][Full Text] [Related]
19. c-Myc is Required for BRAF
Qu Y; Yang Q; Liu J; Shi B; Ji M; Li G; Hou P
Theranostics; 2017; 7(7):2092-2107. PubMed ID: 28656062
[No Abstract] [Full Text] [Related]
20. RBMS3 delays disc degeneration by inhibiting Wnt/β-catenin signaling pathway.
Wang JJ; Liu XY; Du W; Liu JQ; Sun B; Zheng YP
Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):499-507. PubMed ID: 32016951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
